GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Another potential DIC/sepsis competitor is Tifacogin, which NVS picked up when it acquired Chiron earlier this year. Tifacogin failed in a phase-3 sepsis trial in 2001, and hence I had assumed that the compound was dead. However, NVS might be attempting to resuscitate this compound for sepsis. I’ll pay attention to anything that may be revealed at NVS’ R&D Day on Nov 28.<

Oddly, the Tifacogin program appears to have been expedited. NVS’ webcast slides today show it as a planned NDA submission in 2008, a year earlier than NVS’ prior presentation materials. I will attempt to get clarification.